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Abstract | Strong evidence indicates that reduction of salt intake lowers blood pressure and reduces the risk of cardiovascular disease (CVD). The WHO has set a global target of reducing the population salt intake from the current level of  around 10 g per day to <5 g per day. This recommendation has been challenged by several studies, including cohort studies that have suggested a J-shaped relationship between salt intake and CVD risk. However, these studies had severe methodological problems, such as reverse causality and measurement error due to assessment of salt intake by spot urine. Consequently, findings from such studies should not be used to derail critical public-health policy. Gradual, stepwise salt reduction as recommended by the WHO remains an achievable, affordable, effective, and important strategy to prevent CVD worldwide. The question now is how to reduce population salt intake. In most developed countries, salt reduction can be achieved by a gradual and sustained reduction in the amount of salt added to food by the food industry. The UK has pioneered a successful salt-reduction programme by setting incremental targets for >85 categories of food; many other developed countries are following the UK’s lead. In developing countries where most of the salt is added by consumers, public-health campaigns have a major role. Every country should adopt a coherent, workable strategy. Even a modest reduction in salt intake across the whole population can lead to a major improvement in public health and cost-savings.

Introduction
Raised blood pressure (BP) is a leading cause of death and disability worldwide, accounting for approximately 10.7 million deaths per year ADDIN EN.CITE , , predominantly due to cardiovascular disease (CVD). The risk of CVD increases progressively throughout the range of BP, starting at 115/75 mmHg as demonstrated by the meta-analysis of individual data for one million adults in 61 prospective studies.3 The majority of CVD occurs in individuals with high–normal BP of around 130/80 mmHg because of the large number of individuals with BP at this level in the population3. Given that clinical guidelines do not recommend treating these individuals with BP-lowering drugs, dietary and lifestyle changes are the most practical options. Various types of studies have consistently shown that high dietary salt intake is the major cause of raised BP ADDIN EN.CITE 4. A reduction in salt intake lowers BP and reduces CVD risk ADDIN EN.CITE 5-7. The current salt intake among adults in most countries is approximately 10 g per day, with many Asian countries having mean intakes >12 g per day ADDIN EN.CITE , . Numerous leading medical and public-health organizations have recommended a reduction in population salt intake. As part of its strategy, the WHO has set a global target of a 30% reduction in the mean population salt consumption by 2025, with an eventual target of <5 g per day in adults10. The 66th World Health Assembly in 2013 adopted the WHO recommendation HYPERLINK \l "_ENREF_11" \o ",  #8076"  ADDIN EN.CITE <EndNote><Cite><RecNum>8076</RecNum><DisplayText><style face="superscript">11</style></DisplayText><record><rec-number>8076</rec-number><foreign-keys><key app="EN" db-id="xedpvewzms9a5je5vxo522x7sr599zedxxdv">8076</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title>Sixty-sixth World Health Assembly, Follow-up to the Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. 25 May 2013. http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_R10-en.pdf (Accessed 29 August 2017)</title></titles><dates></dates><urls></urls></record></Cite></EndNote>11.
Despite strong evidence supporting a population-wide reduction in salt intake, some scientists continue to publish studies with flawed methodologies, generating controversy and casting doubt on the current public-health policy. In this Review, we provide an analysis of the methodological problems in the studies that have been used to oppose reduction of salt intake for public-health benefit. We also review the latest scientific reports on the link between salt, BP, and CVD, and describe the challenges of reducing population salt intake.

[H1] Salt and blood pressure
The relationship between salt intake and BP is well established, based on a diverse body of evidence including animal experiments, human genetics, physiological studies, epidemiology, migration, population-based intervention studies, and clinical trials ADDIN EN.CITE , . Despite consistent and compelling evidence for a direct linear relationship between salt intake and BP, and the substantial benefits on reducing CVD of lowering population BP, Graudal and colleagues have claimed in a series of meta-analyses, including the latest one published in April 2017 in the Cochrane Library ADDIN EN.CITE 15, that salt reduction causes only a small reduction in BP in individuals who are normotensive. In addition, the percentage reduction in  BP was smaller than the percentage increases in plasma levels of renin, aldosterone, noradrenaline, and lipids, implying that salt reduction might be harmful to health. However, in their meta-analysis, Graudal et al. included trials with a large reduction in salt intake for a very short period of time, such as a few days. A sudden and large reduction in salt intake is well known to cause large compensatory increases in plasma renin activity and angiotensin II level, stimulates the sympathetic nervous system, and reduces plasma volume and thereby increases plasma lipid concentration. A modest reduction in salt intake over a longer period of time, which is the current public-health recommendation, has little effect on these parameters ADDIN EN.CITE , . Meta-analyses of studies lasting just more than 1 month showed that salt reduction did not have an adverse effect on blood lipid ADDIN EN.CITE ,  or catecholamine levels HYPERLINK \l "_ENREF_6" \o "Aburto, 2013 #8057"  ADDIN EN.CITE <EndNote><Cite><Author>Aburto</Author><Year>2013</Year><RecNum>8057</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>8057</rec-number><foreign-keys><key app="EN" db-id="xedpvewzms9a5je5vxo522x7sr599zedxxdv">8057</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Aburto, N. J.</author><author>Ziolkovska, A.</author><author>Hooper, L.</author><author>Elliott, P.</author><author>Cappuccio, F. P.</author><author>Meerpohl, J. J.</author></authors></contributors><auth-address>Nutrition Policy and Scientific Advice Unit, Department of Nutrition for Health and Development, World Health Organization, 1211 Geneva 27, Switzerland.</auth-address><titles><title>Effect of lower sodium intake on health: systematic review and meta-analyses</title><secondary-title>BMJ</secondary-title><alt-title>Bmj</alt-title></titles><periodical><full-title>Bmj</full-title><abbr-1>BMJ (Clinical research ed</abbr-1></periodical><alt-periodical><full-title>Bmj</full-title><abbr-1>BMJ (Clinical research ed</abbr-1></alt-periodical><pages>f1326</pages><volume>346</volume><dates><year>2013</year></dates><isbn>1756-1833 (Electronic)&#xD;0959-535X (Linking)</isbn><accession-num>23558163</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23558163</url></related-urls></urls><electronic-resource-num>10.1136/bmj.f1326</electronic-resource-num></record></Cite></EndNote>6, and was associated with a small physiological increase in plasma renin activity and aldosterone level HYPERLINK \l "_ENREF_5" \o "He, 2013 #8055"  ADDIN EN.CITE <EndNote><Cite><Author>He</Author><Year>2013</Year><RecNum>8055</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>8055</rec-number><foreign-keys><key app="EN" db-id="xedpvewzms9a5je5vxo522x7sr599zedxxdv">8055</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>He, F. J.</author><author>Li, J.</author><author>MacGregor, G. A.</author></authors></contributors><auth-address>Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.</auth-address><titles><title>Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials</title><secondary-title>BMJ</secondary-title><alt-title>Bmj</alt-title></titles><periodical><full-title>Bmj</full-title><abbr-1>BMJ (Clinical research ed</abbr-1></periodical><alt-periodical><full-title>Bmj</full-title><abbr-1>BMJ (Clinical research ed</abbr-1></alt-periodical><pages>f1325</pages><volume>346</volume><dates><year>2013</year></dates><isbn>1756-1833 (Electronic)&#xD;0959-535X (Linking)</isbn><accession-num>23558162</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23558162</url></related-urls></urls><electronic-resource-num>10.1136/bmj.f1325</electronic-resource-num></record></Cite></EndNote>5. Furthermore, salt reduction lowers BP by a similar mechanism to that of thiazide diuretics, which cause similar neural, hormonal, and haemodynamic changes. However, outcome trials have demonstrated that long-term treatment with thiazide diuretics significantly lowers BP and reduces cardiovascular events and mortality ADDIN EN.CITE 17. 
	Meta-analysis of randomized trials with longer-term, modest reduction in salt intake, as currently recommended, have shown significant and, from a population viewpoint, important reductions in BP ADDIN EN.CITE , . A reduction of 4.4 g per day in salt intake led to a decrease in BP of 5.4/2.8 mmHg in individuals with hypertension and 2.4/1.0 mmHg in individuals who were normotensive5. These results are likely to be an underestimate of the full magnitude of the effect because most trials lasted for only a few weeks, with a median duration of 5 weeks and 4 weeks in individuals who were hypertensive or normotensive, respectively. Salt reduction is highly unlikely to have exerted its maximum effect in such a limited time5. A post-hoc analysis of data from a very well-controlled trial — the Dietary Approaches to Stop Hypertension (DASH)-Sodium study ADDIN EN.CITE 18 — has confirmed that salt reduction does not reach full effect on BP over 4 weeks. Only a few randomized trials on salt reduction have had a duration of >1 year ADDIN EN.CITE , . These long-term trials achieved a much smaller reduction in salt intake due to the difficulty for individuals to maintain a lower salt intake for a long period of time, considering the current food environment (widespread presence of salt in almost all processed, canteen, restaurant, and fast food). The modest effect of salt reduction on BP in these long-term trials is, therefore, not surprising. Nevertheless, population-based studies in which salt intake has been reduced across the whole population for several years, as has occurred in the UK by changing the food environment HYPERLINK \l "_ENREF_21" \o "He, 2014 #8551"  ADDIN EN.CITE <EndNote><Cite><Author>He</Author><Year>2014</Year><RecNum>8551</RecNum><DisplayText><style face="superscript">21</style></DisplayText><record><rec-number>8551</rec-number><foreign-keys><key app="EN" db-id="xedpvewzms9a5je5vxo522x7sr599zedxxdv">8551</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>He, F. J.</author><author>Pombo-Rodrigues, S.</author><author>MacGregor, G. A.</author></authors></contributors><auth-address>Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</auth-address><titles><title>Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality</title><secondary-title>BMJ Open</secondary-title><alt-title>BMJ open</alt-title></titles><periodical><full-title>BMJ Open</full-title></periodical><alt-periodical><full-title>BMJ Open</full-title></alt-periodical><pages>e004549</pages><volume>4</volume><number>4</number><dates><year>2014</year></dates><isbn>2044-6055 (Electronic)</isbn><accession-num>24732242</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/24732242</url></related-urls></urls><custom2>3987732</custom2><electronic-resource-num>10.1136/bmjopen-2013-004549</electronic-resource-num></record></Cite></EndNote>21, have demonstrated a much greater reduction in BP  than has been achieved in clinical trials lasting for only a few weeks.
Of note, chronic high-salt intake gradually increases BP throughout life. The INTERSALT study HYPERLINK \l "_ENREF_12" \o ", 1988 #5896"  ADDIN EN.CITE <EndNote><Cite><Year>1988</Year><RecNum>5896</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>5896</rec-number><foreign-keys><key app="EN" db-id="xedpvewzms9a5je5vxo522x7sr599zedxxdv">5896</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title>Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion.</title><secondary-title>BMJ</secondary-title></titles><periodical><full-title>Bmj</full-title><abbr-1>BMJ (Clinical research ed</abbr-1></periodical><pages>319-328</pages><volume>297</volume><number>6644</number><keywords><keyword>Adult</keyword><keyword>Age Factors</keyword><keyword>Alcohol Drinking</keyword><keyword>*Blood Pressure</keyword><keyword>Body Height</keyword><keyword>Body Weight</keyword><keyword>Comparative Study</keyword><keyword>*Cross-Cultural Comparison</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hypertension/epidemiology/urine</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Potassium/*urine</keyword><keyword>Regression Analysis</keyword><keyword>Research Support, Non-U.S. Gov&apos;t</keyword><keyword>Research Support, U.S. Gov&apos;t, P.H.S.</keyword><keyword>Sex Factors</keyword><keyword>Sodium/*urine</keyword><keyword>Statistics</keyword></keywords><dates><year>1988</year><pub-dates><date>Jul 30</date></pub-dates></dates><accession-num>3416162</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=3416162</url></related-urls></urls></record></Cite></EndNote>12 (an international study of electrolyte excretion and BP) demonstrated a direct association between salt intake, as measured by 24-h urinary sodium excretion, and the increase in BP with age: the higher the salt intake, the greater the rise in BP with ageing. In communities with salt intake <3 g per day, the BP did not increase with age.  Reducing the current high level of salt intake in the population is likely, therefore, not only to have a short-term BP-lowering effect, but also to slow the increase in BP with ageing. 
	The question is how far salt intake should be reduced to achieve the greatest BP-lowering effect. Meta-analyses of randomized trials have shown a direct relationship between a reduction in salt intake and a fall in systolic BP ADDIN EN.CITE , . Stronger evidence comes from well-controlled studies with multiple levels of salt intake ADDIN EN.CITE , , including a randomized, double-blind, crossover study in 20 untreated individuals with hypertension whose salt intake was reduced from 11.2 g per day to 6.4 g per day and then to 2.9 g per day ADDIN EN.CITE 23; and the DASH-Sodium trial ADDIN EN.CITE 24 in which salt intake was reduced from 8 g per day to 6 g per day and then to 4 g per day in >400 individuals with normal or mildly elevated BP. Both trials demonstrated a clear dose–response relationship; within the range of 3–12 g per day, a lower salt intake was associated with a lower BP ADDIN EN.CITE , . Additionally, the DASH-Sodium study ADDIN EN.CITE 24 showed that the dose–response relationship was evident not only with the normal American diet, but also with the DASH diet, which is rich in fruits, vegetables, and low-fat dairy products, and that the lowest BP was achieved in individuals eating a combination of the DASH diet and the lowest salt intake (Fig. 1). This dose–response relationship reported in randomized trials is consistent with that observed in epidemiological studies HYPERLINK \l "_ENREF_12" \o ", 1988 #5896"  ADDIN EN.CITE <EndNote><Cite><Year>1988</Year><RecNum>5896</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>5896</rec-number><foreign-keys><key app="EN" db-id="xedpvewzms9a5je5vxo522x7sr599zedxxdv">5896</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title>Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion.</title><secondary-title>BMJ</secondary-title></titles><periodical><full-title>Bmj</full-title><abbr-1>BMJ (Clinical research ed</abbr-1></periodical><pages>319-328</pages><volume>297</volume><number>6644</number><keywords><keyword>Adult</keyword><keyword>Age Factors</keyword><keyword>Alcohol Drinking</keyword><keyword>*Blood Pressure</keyword><keyword>Body Height</keyword><keyword>Body Weight</keyword><keyword>Comparative Study</keyword><keyword>*Cross-Cultural Comparison</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hypertension/epidemiology/urine</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Potassium/*urine</keyword><keyword>Regression Analysis</keyword><keyword>Research Support, Non-U.S. Gov&apos;t</keyword><keyword>Research Support, U.S. Gov&apos;t, P.H.S.</keyword><keyword>Sex Factors</keyword><keyword>Sodium/*urine</keyword><keyword>Statistics</keyword></keywords><dates><year>1988</year><pub-dates><date>Jul 30</date></pub-dates></dates><accession-num>3416162</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=3416162</url></related-urls></urls></record></Cite></EndNote>12, as well as experimental studies in chimpanzees who share 98.4% of their genes with humans ADDIN EN.CITE , . 
	The current recommendation to reduce salt intake from around 10 g per day in most countries to 5–6 g per day will, therefore, lower BP, but evidence indicates that a further reduction to 3 g per day will have an even greater effect on BP. Of note, the current recommendation is based on the feasibility of reducing population salt intake rather than on the potential maximum effect. In the UK, the National Institute for Health and Care Excellence (NICE) recommends a long-term target of 3 g per day for population salt consumption27. In the USA, a target of 6 g per day is recommended for adults, and a lower target of 4 g per day is recommended for approximately half the population: African-American individuals, adults aged ≥51 years, and individuals with high BP, diabetes mellitus, or chronic kidney disease28.

[H1] Salt and cardiovascular disease 
[H3] Predicted effect on CVD from BP lowering with salt reduction 
Compelling evidence exists for a continuous and graded relationship between BP and the risk of CVD, starting at 115/75 mmHg3. Given that a reduction in salt intake lowers BP in individuals who are either hypertensive or normotensive5,6, it would therefore reduce CVD across the population. For example, a 6 g per day reduction in salt intake was estimated to reduce the risk of stroke by 24% and ischaemic heart disease (IHD) by 18%29. In the UK, these reductions would prevent approximately 35,000 CVD deaths per year29. The Global Burden of Disease Study ADDIN EN.CITE 22 showed that around 1.65 million CVD deaths that occurred in 2010 were attributable to high salt consumption; about 84% occurred in developing countries, and 40% were premature (individuals aged <70 years).

[H3] Prospective cohort studies
Over the past 30 years, >30 cohort studies have reported the relationship between salt intake and cardiovascular outcomes. In 2009, a meta-analysis of cohort studies showed a direct association between salt intake and CVD risk30. Two meta-analyses in 2013 supported this finding ADDIN EN.CITE , . However, several subsequent cohort studies have reported a J-shaped association ADDIN EN.CITE 32-35. The latest one, a pooled analysis of four cohort studies, showed that compared with salt intake of 10.0–12.5 g per day, both lower and higher intake were associated with an increased risk of CVD and all-cause mortality ADDIN EN.CITE 34. Following the publication of these results, a working group of the World Heart Federation, the European Society of Hypertension, and the European Public Health Association have suggested that salt intake should be reduced only in countries with a mean population intake of >12.5 g per day, meaning that no reduction in salt intake is needed for the majority of countries ADDIN EN.CITE 36. The reports of a J-shaped association between salt intake and CVD risk  ADDIN EN.CITE 32-35 have clearly created controversy and challenged the current public-health policy on reducing population salt consumption to <5 g per day10. These cohort studies, however, have several severe methodological problems, including reverse causality and systematic and random error in salt-intake assessment ADDIN EN.CITE 37-41.
Reverse causality is a major contributor to the higher risk of CVD with lower salt intake because many of the cohort studies included people with vascular disease or who were at high risk of CVD, such as individuals with chronic kidney disease or diabetes ADDIN EN.CITE 34, a sick population who were likely to eat less food and consume less salt. These individuals might already have been advised to reduce salt intake. The inverse relationship between lower salt and higher risk of CVD might, therefore, be the consequence of the underlying disease rather than the lower salt consumption.
Measurement error in assessing salt intake is another major concern, particularly because some of the cohort studies used a single spot urine sample to estimate an individual’s usual salt intake. Spot urine measures urinary sodium concentration, which is determined not only by salt intake, but also by various other factors such as fluid consumption, time of the day, duration and volume of the collection, an individual’s posture ADDIN EN.CITE , , as well as time and amount of salt in the last meal consumed44. Studies that directly compared salt intake measured by 24‑h urinary sodium with that estimated from spot urinary sodium, have shown that estimates from spot urine are inaccurate, unreliable, not reproducible, and systematically biased ADDIN EN.CITE , , . Furthermore, short-term sodium excretion is regulated by neural hormonal systems (such as the sympathetic nervous system and the renin–angiotensin–aldosterone system) that are associated with cardiovascular outcomes47. Therefore, the sodium concentration in spot urine, which does not reflect a steady state, might reflect cardiovascular risk relating to the control mechanisms for sodium excretion. The salt intake estimated from spot urine also depends on the predicted creatinine excretion, which is calculated using a formula based on age, sex, height, and weight48. Some of these variables are related to health outcomes, which further confounds the relationship between salt intake and outcomes. Owing to these methodological problems, the studies using spot urine cannot be used to inform public-health policy. 
The use of 24-h urinary sodium is considered the gold standard for assessing salt intake. Although one 24-h urine collection is sufficient for estimating the average salt intake in a population, a single 24-h urine collection does not accurately reflect an individual’s usual salt intake due to the large day-to-day variations in salt consumption and excretion ADDIN EN.CITE 49-52. Multiple nonconsecutive 24-h urine collections are needed to assess an individual’s salt intake accurately, which is essential for studies into the association between salt intake and health outcomes41. To date, only three cohort studies have assessed individuals’ salt intake using the gold-standard method of multiple, nonconsecutive 24-h urine collections, and all showed a direct, linear relationship between salt intake and CVD risk ADDIN EN.CITE 53-55. In the Trials of Hypertension Prevention (TOHP) ADDIN EN.CITE , ,  sodium levels were averaged across three to seven collections of 24-h urine over 1.5–4.0 years, and a follow-up of 2,275 participants at 10–15 years after the trial showed a linear 17% increase in CVD risk for every 1 g per day increase in sodium intake at baseline (for every 2.5 g per day of salt) (Fig. 2)  ADDIN EN.CITE 53. A subsequent follow-up of the THOP56 at 20 years demonstrated a linear 12% increase in all-cause mortality for every 1 g per day increase in sodium (for every 2.5 g per day of salt). Importantly, in this study, the direct, linear relationship extended down to a salt level of 3 g per day, which is the long-term target for population salt intake in the UK27. These findings are consistent with the evidence for a strong, direct, linear relationship between salt intake and BP within the range of 3–12 g per day ADDIN EN.CITE , , , and a strong, continuous relationship between BP and CVD ADDIN EN.CITE , . Another study involving patients with chronic kidney disease using the average of three nonconsecutive 24-h urinary sodium excretions over about 2 years of follow-up also showed a strong, linear association between salt intake and CVD risk ADDIN EN.CITE 54.
Almost all cohort studies have investigated the relationship between salt intake at baseline and subsequent occurrence of CVD events or deaths. These studies do not capture changes in salt intake during follow-up. A study published in 2017 compared the use of a single baseline versus multi-year 24-h urine collection for estimation of long-term salt intake and the associated CVD and renal risk55. The results showed that the risk increased by up to 85% with the use of salt intake from 1‑year and 5‑year follow-up instead of single baseline intake. These findings clearly demonstrate the importance of accurately assessing individuals’ long-term salt intake in epidemiological studies. This study also showed that individuals in the highest tertile of salt intake (>10.8 g per day) had a 73–80% increase in CVD events and mortality, and a 44–47% increase in end-stage renal disease or mortality compared with individuals in the lowest tertile (<7.5 g per day)55. These findings are in good agreement with the observed reductions in CVD mortality attributed to the reduction in population salt intake that occurred in countries where salt intake has been reduced, such as Finland and the UK ADDIN EN.CITE , , .

[H3] Population studies
Estimating average population salt intake is far less subject to error than estimating individual intake HYPERLINK \l "_ENREF_41" \o "Cogswell, 2016 #9054"  ADDIN EN.CITE <EndNote><Cite><Author>Cogswell</Author><Year>2016</Year><RecNum>9054</RecNum><DisplayText><style face="superscript">41</style></DisplayText><record><rec-number>9054</rec-number><foreign-keys><key app="EN" db-id="xedpvewzms9a5je5vxo522x7sr599zedxxdv">9054</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Cogswell, M. E.</author><author>Mugavero, K.</author><author>Bowman, B. A.</author><author>Frieden, T. R.</author></authors></contributors><auth-address>From the National Center for Chronic Disease Prevention and Health Promotion, the Division for Heart Disease and Stroke Prevention (M.E.C., K.M., B.A.B.), and the Office of the Director (T.R.F.), Centers for Disease Control and Prevention, Atlanta.</auth-address><titles><title>Dietary Sodium and Cardiovascular Disease Risk--Measurement Matters</title><secondary-title>N Engl J Med</secondary-title><alt-title>The New England journal of medicine</alt-title></titles><periodical><full-title>N Engl J Med</full-title><abbr-1>The New England journal of medicine</abbr-1></periodical><alt-periodical><full-title>N Engl J Med</full-title><abbr-1>The New England journal of medicine</abbr-1></alt-periodical><pages>580-6</pages><volume>375</volume><number>6</number><edition>2016/06/02</edition><keywords><keyword>Cardiovascular Diseases/ etiology</keyword><keyword>Diuretics/therapeutic use</keyword><keyword>Humans</keyword><keyword>Hypertension/prevention &amp; control</keyword><keyword>Risk Assessment</keyword><keyword>Sodium, Dietary/ administration &amp; dosage</keyword></keywords><dates><year>2016</year><pub-dates><date>Aug 11</date></pub-dates></dates><isbn>1533-4406 (Electronic)&#xD;0028-4793 (Linking)</isbn><accession-num>27248297</accession-num><urls></urls><custom2>PMC5381724</custom2><custom6>Hhspa853881</custom6><electronic-resource-num>10.1056/NEJMsb1607161</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>41. This observation might explain the difference between population-based studies, which have shown a reduction in CVD mortality when salt intake was reduced across the population ADDIN EN.CITE , , , and cohort studies using inaccurate individual measures, which have not shown a significant association between salt intake and CVD mortality. 
To date, salt intake has been successfully reduced and the effect on CVD evaluated in only a few countries (Finland, Japan, Portugal, and the UK). In  the late 1960s, it was realised that  the high rate of stroke mortality in Japan was related to the very high levels of salt intake in the population60. The Japanese government initiated a campaign to reduce the amount of salt used by households and, in the following decade, salt intake was reduced from 18 g per day to 14 g per day in the northern parts of the country. This change was associated with a reduction in BP and an approximately 80% reduction in stroke mortality60, despite large increases in the consumption of fat and alcohol, cigarette smoking, and obesity during that time.
In the late 1970s, Finland started a salt-reduction programme through salt-awareness campaigns, working with the food industry and adopting salt labelling legislation ADDIN EN.CITE , , . The programme led to a reduction in salt intake ADDIN EN.CITE ,  from an average of 14 g per day in 1972 to about 9 g per day in 2002, resulting in a decrease of >10 mmHg in both systolic and diastolic BP and a 75–80% reduction in CVD mortality ADDIN EN.CITE , . These results might be attributable to various factors; however, salt reduction is likely to have had an important role, especially in the reductions in BP because both obesity and alcohol consumption increased during that period.
In the 2000s, the UK developed and successfully implemented a programme of voluntary salt reduction in collaboration with the food industry63. The mean salt intake, as measured by 24‑h urinary sodium in a national representative sample of the adult population, was reduced by 15%, from 9.5 g per day in 2003 to 8.1 g per day in 201164. This change led to a reduction in population mean systolic BP of 2.7 mmHg after adjusting for potential confounding factors21 (Fig. 3). During that period, both stroke and IHD mortality were reduced by 36%. Based on the reduction in systolic BP that occurred with salt reduction, around 30% of the reduction in stroke and 20% of the reduction in IHD was estimated to be attributable to the reduction in salt intake. These findings are consistent with predictions from NICE that the reduction in salt intake has prevented approximately 9,000 stroke and IHD deaths per year in the UK27. A cost-effectiveness analysis by NICE has shown that a reduction in salt intake not only saves lives, but also saves money;  the reduction in salt intake achieved in the UK has resulted in health-care savings of approximately £1.5 billion per year27.
In Portugal, salt intake has also been lowered by setting a salt-reduction target for bread, a major contributor to the population’s salt intake. A study in patients with hypertension showed that salt intake, as measured by 24-h urinary sodium, was reduced by 1.6 g per day (from 12.5 g per day in 2003 to 10.9 g per day in 2012)65. This change was accompanied by an average decrease in BP of 7.3/5.8 mmHg and a significant reduction in stroke and IHD mortality during this period65.

[H3] Outcome trials
Evidence from long-term, randomized trials on salt reduction and CVD outcomes in the general population is very limited because of the inherent difficulty in performing such trials, owing to ethical concerns of keeping a group of individuals on a high-salt intake, methodological challenges (particularly compliance with lower-salt intake over many years), cross-contamination between the low and high salt groups, and the very large sample size required to achieve sufficient statistical power. 
 Six randomized trials involving patients with severe heart failure have indicated that salt reduction had no benefits and even increased mortality or rehospitalization66. However, these patients had been receiving multiple drug treatments and were on the verge of salt and water depletion due to the aggressive diuretic treatments combined with angiotensin-converting enzyme inhibitors. The dose of the diuretics was not adjusted when patients were randomly allocated, so it is not surprising that a lower salt intake worsened clinical outcomes. Additionally, all six articles reporting those conclusions were from the same group of researchers, and the integrity of their data has been questioned; two trials presented identical data, and parts of the text were replicated between articles. A meta-analysis of these studies and some of individual trials were retracted after an investigation by the British Medical Journal Publishing Ethics Committee66.
	Several long-term follow-up studies have been performed in individuals who were either hypertensive or normotensive and who previously participated in randomized trials of salt reduction ADDIN EN.CITE , . Meta-analyses of these studies have shown that salt reduction reduces CVD risk ADDIN EN.CITE , . A reduction of 2.0–2.3 g per day in salt intake was associated with a 20% (P < 0.05) reduction in CVD events and a nonsignificant 5–7% reduction in all-cause mortality7. These results provide further support for a reduction in population salt intake.

[H1] Challenges of reducing population salt intake
The evidence supporting a reduction in population salt intake is robust and persuasive. How to reduce salt intake to the WHO-recommended level remains an open question. In most developed countries, approximately 80% of the salt is added by the food industry68. Therefore, persuading all food manufacturers and retailers to make a gradual and sustained reduction in the amount of salt they add to food is vital. The UK has pioneered a successful salt-reduction programme. Under the leadership of Consensus Action on Salt and Health69 (a non-governmental organization) and the Food Standards Agency (a quasi-governmental organization), the UK set incrementally lower salt targets for >85 categories of food for the industry to achieve within a clear timeframe, along with an independent, transparent monitoring programme. This ensures a ‘level playing field’ for the food industry, because all the major food companies have to aim for the same targets. Substantial progress has been made since the programme started in 2003–2004, and the salt content in many foods has been reduced by 20–50% ADDIN EN.CITE , . These reductions have been made gradually and slowly and, therefore, the public are largely unaware of these changes and there is no loss of sales. The average salt intake in the UK has fallen by 15%, which has resulted in significant reductions in population BP and CVD mortality21.
Many other developed countries, such as Australia, Canada, and the USA, are following the UK’s model by setting salt-reduction targets ADDIN EN.CITE 71-73. In 2016, the FDA proposed voluntary salt targets for approximately 150 categories of food74. These targets, if achieved, would reduce salt intake in the USA to 7.5 g per day within 2 years and to around 6.0 g per day in 10 years. Several countries, including South Africa, have set mandatory salt-reduction targets. Evidence shows that regulatory and legislative approaches are more effective than voluntary ones, but the complicated legislative processes in many countries cause long delays to action. Therefore, the best way to proceed is to start with voluntary salt-reduction targets while regulation or legislation is enacted.
Most developing countries are lagging behind, despite having a very high salt intake, and >80% of the global salt-related disease burden occurs in these countries. Action is urgently needed. In many developing countries, most of the salt in the diet is added by the consumer during cooking or in sauces; a salt-awareness campaign is needed to encourage individuals to reduce the amount of salt used during food preparation at home. Persuading people to change their dietary behaviour is a difficult task, and no country so far has been successful in reducing population salt intake in such settings.
Nevertheless, several new approaches have been developed. For example, in a study in northern China, primary-school children were educated about the harmful effects of salt on health and the means to reduce salt intake as part of their usual health education lessons75. Children were empowered to educate the whole family. This approach has been shown to be feasible and effective by a well-controlled, cluster randomized trial in 28 schools with 279 children and 553 adult family members75. Salt intake, as measured by repeated 24‑h urinary sodium excretions, decreased by 1.9 g per day in children and 2.9 g per day in adults after one school term of approximately 3.5 months75. Another approach to reducing salt intake in a population in which most of the salt is added by the consumer is to replace the usual salt with a mineral salt that is low in sodium and high in potassium. A cluster randomized trial involving 1981 elderly veterans who lived in a veteran’s retired home in northern Taiwan has shown that the use of a potassium-enriched salt, instead of the usual salt, was associated with a lower CVD mortality during a follow-up of 31 months76. The observed effect in this study is likely to be attributable to the combination of a reduction in salt intake and an increase in potassium consumption.
To date, >70 countries have started salt-reduction initiatives, with the majority adopting multifaceted strategies including consumer education, reformulation, target setting, and improvement of labelling, as well as taxation on highly salted foods ADDIN EN.CITE 73. An important barrier is the rigorous opposition from the food industry to prevent government from taking action. Some members of the food industry are reluctant to reduce salt in their food products for commercial reasons. Salt makes cheap, unpalatable food edible at little additional cost. Chronic high-salt intake supresses the salt taste receptors and leads to habituation to salted foods and, therefore, increases demand. Furthermore, salt in meat products, combined with other water-binding chemicals, increases the amount of water that is contained in the meat, which increases the product weight by up to 20% at no extra cost. Additionally, a high-salt intake increases thirst and the sales of soft drinks and mineral water ADDIN EN.CITE , . Even if these commercial reasons need to be acknowledged, the food industry should not be allowed to stand in the way of salt reduction because a reduction in population salt intake will have an immense benefit to public health. The industry should not resist gradually reducing the extremely high levels of salt in many foods that they produce. Indeed, lower-salt foods are healthier and will lower BP and reduce the risk of CVD and other noncommunicable diseases, such as renal disease, stomach cancer, and osteoporosis ADDIN EN.CITE ,  HYPERLINK \l "_ENREF_4" \o "He, 2010 #7823" . The population will live longer and, as a result, the number of consumers with increase. 

[H1] Conclusions
The totality of the evidence strongly supports the current public-health policy for a population-wide reduction in salt intake. Indeed, evidence for the effect of salt on health is more, or at least as robust as that for other dietary and lifestyle changes, such as eating more fruit and vegetables, increasing physical activity, and reducing smoking; of note, no randomized trials linking these factors to CVD are available. Taking action to improve these factors, unlike salt, requires individuals to make major changes in their eating habits and lifestyles. From a public-health perspective, salt reduction is one of the most cost-effective, feasible, and affordable measures to prevent CVD and other noncommunicable diseases. Paradoxical findings from studies with severe methodological problems should not be used to prevent action to reduce salt intake. Several countries have been successful in reducing salt intake; the major challenge now is to expand this to all other countries to lower salt intake to the WHO target. The benefits will be enormous, including prevention of >1.6 million CVD-related deaths per year10 and major cost-savings to individuals, their families, and health services.
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Key points
Salt reduction causes a dose-dependent reduction in blood pressure; within the range of 3–12 g per day, the lower the salt intake, the lower the blood pressure
Prospective cohort studies with salt intake measured by multiple 24-h urine collections demonstrate a direct linear relationship with cardiovascular events and all-cause mortality, down to a salt intake of 3 g per day
The totality of the evidence strongly supports population-wide reduction in salt intake; paradoxical J-shaped findings from studies with methodological problems should not derail action to reduce salt consumption
Every country should implement a strategy to reduce salt intake to the WHO target of 5 g per day; this action will result in major public-health improvements and cost savings 

Figure 1 | Salt intake and blood pressure. Salt intake measured by 24-h urinary sodium excretion during the DASH-Sodium trial ADDIN EN.CITE 24 in all participants (169 with hypertension and 243 normotensive) receiving a normal American (control) diet or the DASH diet. 

Figure 2 | Salt intake and cardiovascular risk. Hazard ratio for cardiovascular events and deaths according to mean salt intake measured by three to seven 24-h urinary sodium excretions in TOHP participants who were not in the salt-reduction group, followed up for 10–15 years after the trial. Rug plot indicates distribution of sodium excretion. Adapted from reference 53.

Figure 3 | Salt intake, blood pressure and cardiovascular mortality. Changes in salt intake (measured by 24-h urinary sodium excretion),  blood pressure, and stroke and ischaemic heart disease (IHD) mortality in England from 2003 to 2011. *P < 0.05. ***P < 0.001 for trend. 
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